Stramsen is offering huge discounts of up to 80% for its Reg A and Reg D offerings
HOUSTON, March 11, 2025 — In a strategic move to enhance investor relations and capital management capabilities, Stramsen Biotech Inc. has forged a powerful alliance with Nasdaq Private Market (NPM), a specialized division of the renowned Nasdaq exchange. This New York-based broker-dealer excels in facilitating transactions in both private primary and secondary markets, providing unparalleled opportunities for the sale of company and shareholders’ shares. This partnership not only streamlines Stramsen’s ability to connect with potential investors but also empowers the company to manage capital structure with an unprecedented efficiency.
Stramsen Biotech Inc. is pleased to present an exceptional investment opportunity to a diverse range of investors, including individuals, hedge funds, venture capitalists as well as institutional investors. As the company approaches the final stages of its Regulation A offering approval process, we are excited to announce that we are currently raising funds through a Regulation D offering. To ensure a seamless and professional investment experience, we have partnered with NPM, a prestigious broker-dealer to facilitate capital raising for both our Regulation A and Regulation D offerings.
Stramsen Biotech Inc. is currently offering a one-time discount of approximately 86% for Reg A, bringing the current share price down to $1.20 per share. Investors’ private assets will increase by about 623% based on a single investment purchase for Reg A. The company is also offering a one-time discount of approximately 91% for Reg D, bringing the current share price down to $0.80 per share. Investors’ private assets will increase by about 983% based on a single purchase of shares for Reg D. Stramsen is currently valued at $6.5 billion and the current price per share is $8.67. Private asset increases are based on a single purchase of Stramsen Biotech shares.
Stramsen Biotech Inc. is a biopharmaceutical company developing innovative medicines for infectious and non-infectious diseases. The global pharmaceutical market, valued at $1.6 trillion in 2023, is projected to reach $2.4 trillion by 2029. Stramsen aims to capture 1-5% of this market within 5-15 years, with expected annual gross revenue between $10 billion and $85 billion in the next decade.
Stramsen Biotech, Inc. will donate a total of 100,000 shares of the company’s common stock to eligible non-profit organizations that work with disabled military veterans in the US, children who live in poverty in developing countries, or refugee camps overseas, and select individual veterans.
Homepage – Nasdaq Private Market
www.StramsenBiotech.com
https://www.facebook.com/StramsenBiotech
https://twitter.com/stramsen
Contact:
Scott Villwock
President & CEO
7139551156
[email protected]
SOURCE Stramsen Biotech Inc
